All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @sarahbaker__ on TikTok · 38s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @sarahbaker__'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Come take my second week of compound semaglotide with me.
  2. 0:06Here is the bag with the syringes and the compound medication comes in this little vial.
  3. 0:13You measure out the units that your doctor prescribes for you and then once your medication is all measured out in the syringe,
  4. 0:26clean the area that you're going to inject your medication in.
  5. 0:30I typically alternate between my stomach and my arm and you are done. Easy peasy lemon squeezy.

@sarahbaker__'s compound semaglutide journey, fact-checked

sarahbaker_

TikTok creator

271.7K viewsWatch on TikTok

Quick answer

The creator demonstrates subcutaneous self-injection of compounded semaglutide, drawing doses measured in units from a multi-dose vial. This technique mirrors standard GLP-1 injection practice, but the unit-based dosing language is a documented FDA safety concern because compounded semaglutide vials vary in concentration across pharmacies, making unit measurements unreliable without knowing the specific mg/mL formulation. The video does not distinguish between compounded and FDA-approved semaglutide formulations, which have different regulatory and evidentiary standing.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @sarahbaker__'s compound semaglutide journey, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@sarahbaker__'s compound semaglutide journey, fact-checked" from sarahbaker_. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator demonstrates subcutaneous self-injection of compounded semaglutide, drawing doses measured in units from a multi-dose vial.

The reason this review is not generic is the source wording and the canonical claim label "glp1 week 2 compound semaglutide from mochi health joinmochi mo." In this clip, the useful excerpt is: "Come take my second week of compound semaglotide with me." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Rotating injection sites between the abdomen and upper arm, as the creator does, is clinically correct and reduces lipohypertrophy risk.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator demonstrates subcutaneous self-injection of compounded semaglutide, drawing doses measured in units from a multi-dose vial.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator demonstrates subcutaneous self-injection of compounded semaglutide, drawing doses measured in units from a multi-dose vial. This technique mirrors standard GLP-1 injection practice, but the unit-based dosing language is a documented FDA safety concern because compounded semaglutide vials vary in concentration across pharmacies, making unit measurements unreliable without knowing the specific mg/mL formulation. The video does not distinguish between compounded and FDA-approved semaglutide formulations, which have different regulatory and evidentiary standing.
  • The FDA issued a 2023 safety communication specifically about dosing errors with compounded semaglutide, including cases where patients received doses 10 times too high due to unit-versus-milligram confusion.
  • Rotating injection sites between the abdomen and upper arm, as the creator does, is clinically correct and reduces lipohypertrophy risk.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The FDA issued a 2023 safety communication specifically about dosing errors with compounded semaglutide, including cases where patients received doses 10 times too high due to unit-versus-milligram confusion.
  • Rotating injection sites between the abdomen and upper arm, as the creator does, is clinically correct and reduces lipohypertrophy risk.
  • Wilding et al. (2021, NEJM) established semaglutide's weight-loss efficacy using Novo Nordisk's manufactured formulation, not compounded versions. Assuming identical outcomes is not evidence-based.
  • Compounded semaglutide is not FDA-approved and has not undergone the same safety, purity, and efficacy review as Ozempic or Wegovy.
  • As of early 2025, the FDA declared the semaglutide shortage resolved, which has significant legal implications for compounding pharmacies still producing it.
  • Anyone using compounded semaglutide should confirm the exact concentration in mg/mL from their pharmacy, not just the unit dose, to avoid dosing errors.
  • Mochi Health operates as a telehealth prescriber, not a pharmacy. Patients receive compounded semaglutide from third-party compounding pharmacies whose formulations may differ from each other.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @sarahbaker__ actually say?

In a 271K-view TikTok, @sarahbaker__ walked viewers through her second week of compounded semaglutide from Mochi Health. She described drawing up the dose using units marked on the syringe, cleaning the injection site, and alternating between her stomach and arm. Her summary: "easy peasy lemon squeezy."

The video is light on medical detail, which is both its appeal and its problem. She doesn't mention dose, side effects, or the fact that compounded semaglutide carries regulatory baggage that brand-name versions don't. For 271,000 viewers, some of whom are almost certainly considering this drug, that omission matters. To her credit, she does say "your doctor prescribes" the units, which at least frames this as a supervised process.

Does the science back this up?

The injection technique she describes is broadly consistent with standard subcutaneous injection practice. That part checks out. Semaglutide is administered subcutaneously, and rotating injection sites, including the abdomen and upper arm, is standard guidance supported by the drug's prescribing information and common clinical practice.

What's less clear is whether compounded semaglutide delivers what brand-name semaglutide does. The FDA does not approve compounded drugs, and it has warned explicitly that compounded semaglutide products have not been shown to be safe or effective. A 2023 FDA alert noted reports of hospitalizations tied to dosing errors with compounded semaglutide, partly because patients were drawing doses in units rather than milligrams, which creates real confusion. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) that established semaglutide's efficacy used the commercially manufactured Novo Nordisk formulation, not compounded versions. Assuming identical outcomes is a leap the evidence doesn't support.

What did they get wrong (or right)?

The injection rotation advice is right. Alternating between the stomach and arm reduces the risk of lipohypertrophy, which is localized fat buildup from repeated injections in the same spot. That's real guidance.

What she gets wrong, or at least dangerously incomplete on, is the framing of compounded semaglutide as a routine, breezy experience. Drawing doses in "units" is where things get risky. Unlike insulin, where units are a standardized measurement tied to a specific concentration, compounded semaglutide vials can vary in concentration between compounding pharmacies. The FDA flagged this exact issue in 2023, noting that patients and providers were confusing units with milligrams and administering doses up to 10 times too high or too low. "Measuring out the units your doctor prescribes" sounds simple, but it assumes the viewer's vial has the same concentration as hers, which it may not.

  • Site rotation: accurate and good advice
  • Doctor-supervised dosing: correctly noted
  • Framing compounded semaglutide as equivalent to Ozempic or Wegovy: not stated directly but strongly implied
  • Dose-in-units language: potentially dangerous without concentration context

What should you actually know?

Compounded semaglutide exists in a legal and medical grey zone that this video does nothing to acknowledge. The FDA placed compounded semaglutide on its shortage list, which temporarily allowed compounding pharmacies to produce it legally. As of early 2025, the FDA declared the shortage resolved, which means many compounding pharmacies can no longer legally produce it. Patients currently using it from companies like Mochi Health are navigating an actively shifting regulatory situation.

That doesn't mean everyone on compounded semaglutide is in danger. But it does mean that a 60-second "come take my injection with me" video is not an appropriate vehicle for introducing people to this drug. The SURMOUNT and STEP trial data are strong for the approved drugs. The compounded versions have no equivalent evidence base, and the concentration variability problem is a documented safety issue, not a theoretical one.

If you are considering compounded semaglutide, get clarity from your prescriber on the exact concentration in your vial in mg/mL, not just the units. Confirm your pharmacy's accreditation. And understand that what works for someone on TikTok may not reflect your formulation, your dose, or your health history.

The bottom line

@sarahbaker__ is sharing a personal experience, not giving medical advice, and her injection technique is largely sound. But the casual framing of compounded semaglutide as interchangeable with brand-name versions, combined with dose-in-units language that the FDA has specifically identified as a source of serious dosing errors, makes this video more misleading than helpful for anyone using it as a starting point. Give credit where it's due, but don't let the cheerful tone substitute for the context this drug actually requires.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

sarahbaker_ · TikTok creator

271.7K views on this video

Week 2 compound semaglutide from Mochi Health #joinmochi #mochihealth #semaglutide #weightlossjouney #fitnessjourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the fda?

The FDA issued a 2023 safety communication specifically about dosing errors with compounded semaglutide, including cases where patients received doses 10 times too high due to unit-versus-milligram confusion.

What does the video say about rotating injection sites between the abdomen?

Rotating injection sites between the abdomen and upper arm, as the creator does, is clinically correct and reduces lipohypertrophy risk.

What does the video say about wilding et al. (2021, nejm) established semaglutide's weight-loss efficacy using?

Wilding et al. (2021, NEJM) established semaglutide's weight-loss efficacy using Novo Nordisk's manufactured formulation, not compounded versions. Assuming identical outcomes is not evidence-based.

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-approved and has not undergone the same safety, purity, and efficacy review as Ozempic or Wegovy.

What does the video say about as of early 2025, the fda declared the semaglutide shortage?

As of early 2025, the FDA declared the semaglutide shortage resolved, which has significant legal implications for compounding pharmacies still producing it.

What does the video say about anyone using compounded semaglutide should confirm the exact concentration in?

Anyone using compounded semaglutide should confirm the exact concentration in mg/mL from their pharmacy, not just the unit dose, to avoid dosing errors.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by sarahbaker_, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.